数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   SNDX
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

股本结构

单位：万股
公告日期 2024-04-02 2024-04-02 2024-02-27 2024-02-27 2023-12-15 2023-11-02
证券总股本 8497.97 8497.62 8496.55 8482.66 8045.15 6964.07
普通股本 8497.97 8497.62 8496.55 8482.66 8045.15 6964.07
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2024-03-20 2024-03-08 2024-02-19 2023-12-31 2023-12-19 2023-10-27
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2024-04-02 8497.97 未披露 定期报告 2024-03-20
2024-04-02 8497.62 未披露 定期报告 2024-03-08
2024-02-27 8496.55 未披露 定期报告 2024-02-19
2024-02-27 8482.66 未披露
更多>>
From December 31,2022 to December 31,2023 Proceeds from direct offering, net of $14,044 offering expenses Proceeds from at-the-market offerings, net of $1,086 offering expense Stock purchase under ESPP Pre-funded warrant cashless exercise Vesting of RSU Proceeds from exercise of stock options
2023-12-31
2023-12-15 8045.15 未披露
更多>>
Common stock offered 10,810,810 shares by the company
2023-12-19
2023-11-02 6964.07 未披露 定期报告 2023-10-27
2023-11-02 6963.82 未披露
更多>>
From June 30, 2023 to September 30, 2023 Stock purchase under ESPP Proceeds from exercise of stock options
2023-09-30
2023-08-03 6948.41 未披露 定期报告 2023-07-27
2023-08-03 6943.12 未披露 定期报告 2023-06-30
2023-05-08 6882.13 未披露 定期报告 2023-05-03
2023-05-08 6849.54 未披露 定期报告 2023-03-31
2023-04-07 6849.54 未披露 定期报告 2023-03-22
2023-02-28 6844.26 未披露 定期报告 2023-02-24
2023-02-28 6811.14 未披露
更多>>
From December 31, 2021 to December 31, 2022 Proceeds from at-the-market offering, net of $600 offering expenses Proceeds from direct offering, net of $10,535 offering expenses Stock purchase under ESPP Pre-funded warrant cashless exercise Vesting of RSU Proceeds from exercise of stock options
2022-12-31
2022-12-14 6810.09 未披露 定期报告 2022-12-14
2022-12-07 6704.17 未披露
更多>>
Common stock offered 6,818,182 shares by the company
2022-12-09
2022-11-03 6022.35 未披露 定期报告 2022-11-02
2022-11-03 6012.27 未披露 定期报告 2022-09-30
2022-08-08 5656.52 未披露 定期报告 2022-08-05
2022-08-08 5639.97 未披露
更多>>
From March 31, 2022 to June 30, 2022 Proceeds from ATM sales Proceeds from exercise of stock options
2022-06-30
2022-05-09 5623.23 未披露 定期报告 2022-05-06
2022-05-09 5503.09 未披露
更多>>
From December 31, 2021 to March 31, 2022 Stock purchase under ESPP Proceeds from exercise of stock options
2022-03-31
2022-03-29 5501.52 未披露 定期报告 2022-03-16
2022-03-01 5501.22 未披露 定期报告 2022-02-25
2022-03-01 5498.31 未披露
更多>>
From December 31, 2020 to December 31, 2021 Proceeds from At-the-market offering, net of $159 offering expenses Proceeds from direct offering, net of $5,332 offering expenses Stock purchase under ESPP Pre-funded warrant exercise Proceeds from Incyte Share Purchase Agreement Vesting of RSU Proceeds from exercise of stock options
2021-12-31
2021-12-20 5200.77 未披露
更多>>
1.Common stock to be offered by company 3,157,144 shares. 2.The above discussion is based on 48,850,539 shares of common stock outstanding as of September 30, 2021.
2021-12-20
2021-12-09 5027.21 未披露
更多>>
1.Common stock to be offered by company 1,421,523 shares. 2.The above discussion is based on 48,850,539 shares of common stock outstanding as of September 30, 2021.
2021-12-09
2021-11-15 4939.21 未披露 定期报告 2021-11-11
2021-11-15 4885.05 未披露
更多>>
From June 30, 2021 to September 30, 2021 Stock purchase under ESPP Proceeds from exercise stock options
2021-09-30
2021-08-09 4862.76 未披露 定期报告 2021-08-06
2021-08-09 4861.66 未披露
更多>>
From March 31, 2021 to June 30, 2021 Proceeds from ATM Offering, net of $200 offering expenses Proceeds from exercise stock options
2021-06-30
2021-05-11 4824.86 未披露
更多>>
From December 31, 2020 to March 31, 2021 Stock purchase under ESPP Prefunded warrant exchange Proceeds from exercise of stock options
2021-03-31
2021-03-12 4823.58 未披露 定期报告 2021-03-10
2021-03-12 4788.12 未披露
更多>>
From December 31, 2019 to December 31, 2020 Proceeds from direct offering, net of $7,132 offering expenses Proceeds from direct offering, net of $93 offering expenses Proceeds from direct offering, net of $8,770 offering expenses Stock purchase under ESPP Pre-funded warrant exercise Exercise of Series 1 and Series 2 warrants Proceeds from exercise of stock options
2020-12-31
2020-12-11 4636.92 未披露
更多>>
1.Common stock to be offered by the company: 5,434,783 shares. 2.The above discussion is based on 40,934,402 shares of common stock outstanding, which represents 38,834,381 shares of common stock outstanding as of September 30, 2020.
2020-12-11
2020-11-05 4086.92 未披露 定期报告 2020-11-04
2020-11-05 3883.44 未披露
更多>>
From June 30, 2020 to September 30, 2020 Stock purchase under ESPP Exercise Series 1 and Series 2 warrants Proceeds from exercise of stock options
2020-09-30
2020-08-06 3854.92 未披露 定期报告 2020-08-05
2020-08-06 3851.27 未披露
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common stock in exchange for pre-funded warrants Exercise Series 1 and Series 2 warrants Proceeds from direct offering, net of $7,099 offering expenses Proceeds from exercise of stock options
2020-06-30
2020-05-07 3609.49 未披露 定期报告 2020-05-06
2020-05-04 3573.28 未披露
更多>>
1.Common stock offered 5,555,556 shares 2.based on 30,177,203 shares of our common stock outstanding
2020-05-04
2020-05-07 3024.08 未披露
更多>>
From December 31, 2019 to March 31, 2020 Stock purchase under ESPP Proceeds from direct offering, net of $93 offering expenses Proceeds from exercise of stock options
2020-03-31
2020-03-05 3024.08 未披露 定期报告 2020-03-04
2020-02-04 3017.72 未披露 定期报告 2020-02-04
2019-11-07 2714.05 未披露
更多>>
from June 30, 2019 to September 30, 2019 Stock purchase under ESPP Proceeds from exercise of stock options
2019-09-30
2019-08-07 2713.68 未披露 定期报告 2019-08-06
2019-08-07 2711.79 未披露
更多>>
From March 31, 2019 to June 30, 2019 Proceeds from exercise of stock options
2019-06-30
2019-05-08 2709.58 未披露
更多>>
From December 31, 2018 to March 31, 2019 Stock purchase under ESPP Proceeds from 'at-the-market' offering, net of $34 offering expenses Proceeds from direct offering, net of $1,571 in common stock warrants, $78 offering expenses
2019-03-31
2019-03-07 2500.07 未披露 定期报告 2019-03-06
2019-03-07 2483.60 未披露
更多>>
from December 31,2017 to December 31,2018 Proceeds from "At-the-market" offering, net Proceeds from exercise of stock options Stock issuance due to warrant exercise, cashless Stock purchase under ESPP Retirement of common stock in exchange for common stock warrant
2018-12-31
2018-11-05 2483.60 未披露 定期报告 2018-11-02
2018-11-05 2405.14 未披露
更多>>
from December 31, 2017 to September 30, 2018 Stock purchase under ESPP Proceeds from 'At-the-market' offering, net Stock issuance due to warrant exercise, cashless Proceeds from exercise stock options Retirement of common stock in exchange for common stock warrant
2018-09-30
2018-08-08 2335.50 未披露 定期报告 2018-08-06
2018-08-08 2270.58 未披露
更多>>
from December 31, 2017 to June 30, 2018 Stock purchase under ESPP Stock issuance due to warrant exercise, cashless Proceeds from exercise stock options Retirement of common stock in exchange for common stock warrant
2018-06-30
2018-05-09 2470.58 未披露 定期报告 2018-05-08
2018-05-09 2469.79 未披露
更多>>
from December 31, 2017 to March 31, 2018 Stock purchase under ESPP Stock issuance due to warrant exercise, cashless
2018-03-31
2018-03-08 2469.79 未披露 定期报告 2018-03-05
2018-03-08 2439.00 未披露
更多>>
from December 31, 2016 to December 31, 2017 Proceeds from follow on offering, net of offering cost of $3,665 Proceeds from exercise of stock options Vesting of restricted stock Proceeds from "At-the-market" offering, net Proceeds from direct stock placement, net
2017-12-31
2017-10-20 2438.99 未披露 定期报告 2017-10-20
2017-11-08 2231.30 未披露
更多>>
from December 31, 2016 to September 30, 2017 Proceeds from follow on offering, net of offering cost of $3,665 Proceeds from exercise of stock options Vesting of restricted stock Proceeds from “At-the-market” offering, net
2017-09-30
2017-08-10 2222.00 未披露 定期报告 2017-08-10
2017-08-10 2221.98 未披露
更多>>
from December 31, 2016 to June 30, 2017 Proceeds from follow-on offering, net of offering costs of $3,665 Proceeds from exercise stock options Vesting of restricted stock
2017-06-30
2017-05-09 1825.59 未披露 定期报告 2017-05-02
2017-05-09 1824.49 未披露 定期报告 2017-03-31
2017-04-07 1825.19 未披露 定期报告 2017-03-22
2017-03-14 1824.44 未披露 定期报告 2017-03-07
2017-03-14 1821.52 未披露
更多>>
from December 31, 2015 to December 31, 2016 Coversion of preferred stock into common stock Proceeds from initial public offering, net of offering costs of $7,186 Exercise of stock options Vesting of restricted stock
2016-12-31
2016-11-14 1819.34 未披露 定期报告 2016-11-07
2016-11-14 1817.98 1000.00
更多>>
from December 31, 2015 to September 30, 2016 Conversion of preferred stock into common stock Proceeds from IPO, net of offering costs of $7,186 Exercise of stock options Vesting of restricted stock
2016-09-30
2016-08-15 1778.22 未披露 定期报告 2016-08-08
2016-08-15 1777.05 未披露
更多>>
from December 31, 2015 to June 30, 2016 Proceeds from IPO, net of offering costs of $7,186 Conversion of preferred stock into common stock Vesting of restricted stock On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
2016-06-30
2016-05-16 1778.22 未披露
更多>>
On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
2016-05-05
2016-05-16 1776.90 未披露
更多>>
from December 31, 2015 to March 31, 2016 Proceeds from IPO, net of offering costs of $7,186 Conversion of preferred stock into common stock Vesting of restricted stock On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
2016-03-31
2016-03-03 1737.27 未披露
更多>>
The number of shares of our common stock outstanding immediately following this offering set forth above is based on 12,972,675 shares of our common stock outstanding as of December 31, 2015 (including 14,684 shares of unvested restricted stock subject to repurchase by us), which gives effect to the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 12,872,551 shares of our common stock upon completion of this offering. On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
2016-03-03
2016-02-22 8.54 1343.29
更多>>
From December 31, 2014 to December 31, 2015 Issuance of Series B-1 convertible preferred stock in January 2015 in conjunction with KHK Agreement Issuance of Series C-1 convertible preferred stock in June 2015, net of issuance costs of $0.2 million Conversion of 2014 Notes into Series C-1 Issuance of Series C-1 convertible preferred stock in August 2015, net of issuance costs of $0.2 million Exercise of stock options Vesting of restricted stock The accompanying consolidated financial statements give effect to a 1-for-1.25 reverse stock split of the common stock and convertible preferred stock of Syndax Pharmaceuticals, Inc. and subsidiaries (the “Company”), which will take place prior to the effective date of the registration statement.
2015-12-31
2016-01-04 10.28 1679.12
更多>>
from December 31, 2014 to September 30, 2015 Issuance of Series B-1 convertible preferred stock in January 2015 in conjunction with KHK Agreement Issuance of Series C-1 convertible preferred stock in June 2015, net of issuance costs of $0.2 million Conversion of 2014 Notes into Series C-1 Issuance of Series C-1 convertible preferred stock in August 2015, net of issuance costs of $0.2 million Exercise of common stock options Vesting of restricted stock
2015-09-30
2014-06-05 7.32 850.80
更多>>
On June 3, 2014, the Company effected a 1-for-12.3 reverse stock split of the Company’s common stock and convertible preferred stock. All share and per share data shown in the accompanying interim financial statements and related notes have been retroactively revised to reflect the reverse stock split.
2014-06-04
2014-03-27 87.00 10464.94
更多>>
from December 31,2012 to December 31,2013 Conversion of Series A convertible preferred stock into Series A-1 convertible preferred stock and cancellation of warrants pursuant to the recapitalization Conversion of convertible notes and accrued interest into Series B-1 convertible preferred stock and cancellation of warrants and forced conversion into Series B convertible preferred stock pursuant to the recapitalization Issuance of Series B-1 convertible preferred stock: In March 2013, net of offering costs of $626 and tranche obligation of $206 In April 2013 In July 2013, net of tranche obligation of $754 and beneficial conversion feature of $452 In August 2013, net of offering costs of $365 and tranche obligation of $1,964 and beneficial conversion feature of $842 In November 2013, including $7,008 de-recognition of remaining tranche obligation Forced conversion of Series A-1 convertible preferred into Series A convertible preferred stock Issuance of common stock as consideration for license fees
2013-12-31
From December 31,2022 to December 31,2023 Proceeds from direct offering, net of $14,044 offering expenses Proceeds from at-the-market offerings, net of $1,086 offering expense Stock purchase under ESPP Pre-funded warrant cashless exercise Vesting of RSU Proceeds from exercise of stock options
Common stock offered 10,810,810 shares by the company
From June 30, 2023 to September 30, 2023 Stock purchase under ESPP Proceeds from exercise of stock options
From December 31, 2021 to December 31, 2022 Proceeds from at-the-market offering, net of $600 offering expenses Proceeds from direct offering, net of $10,535 offering expenses Stock purchase under ESPP Pre-funded warrant cashless exercise Vesting of RSU Proceeds from exercise of stock options
Common stock offered 6,818,182 shares by the company
From March 31, 2022 to June 30, 2022 Proceeds from ATM sales Proceeds from exercise of stock options
From December 31, 2021 to March 31, 2022 Stock purchase under ESPP Proceeds from exercise of stock options
From December 31, 2020 to December 31, 2021 Proceeds from At-the-market offering, net of $159 offering expenses Proceeds from direct offering, net of $5,332 offering expenses Stock purchase under ESPP Pre-funded warrant exercise Proceeds from Incyte Share Purchase Agreement Vesting of RSU Proceeds from exercise of stock options
1.Common stock to be offered by company 3,157,144 shares. 2.The above discussion is based on 48,850,539 shares of common stock outstanding as of September 30, 2021.
1.Common stock to be offered by company 1,421,523 shares. 2.The above discussion is based on 48,850,539 shares of common stock outstanding as of September 30, 2021.
From June 30, 2021 to September 30, 2021 Stock purchase under ESPP Proceeds from exercise stock options
From March 31, 2021 to June 30, 2021 Proceeds from ATM Offering, net of $200 offering expenses Proceeds from exercise stock options
From December 31, 2020 to March 31, 2021 Stock purchase under ESPP Prefunded warrant exchange Proceeds from exercise of stock options
From December 31, 2019 to December 31, 2020 Proceeds from direct offering, net of $7,132 offering expenses Proceeds from direct offering, net of $93 offering expenses Proceeds from direct offering, net of $8,770 offering expenses Stock purchase under ESPP Pre-funded warrant exercise Exercise of Series 1 and Series 2 warrants Proceeds from exercise of stock options
1.Common stock to be offered by the company: 5,434,783 shares. 2.The above discussion is based on 40,934,402 shares of common stock outstanding, which represents 38,834,381 shares of common stock outstanding as of September 30, 2020.
From June 30, 2020 to September 30, 2020 Stock purchase under ESPP Exercise Series 1 and Series 2 warrants Proceeds from exercise of stock options
From March 31, 2020 to June 30, 2020 Issuance of common stock in exchange for pre-funded warrants Exercise Series 1 and Series 2 warrants Proceeds from direct offering, net of $7,099 offering expenses Proceeds from exercise of stock options
1.Common stock offered 5,555,556 shares 2.based on 30,177,203 shares of our common stock outstanding
From December 31, 2019 to March 31, 2020 Stock purchase under ESPP Proceeds from direct offering, net of $93 offering expenses Proceeds from exercise of stock options
from June 30, 2019 to September 30, 2019 Stock purchase under ESPP Proceeds from exercise of stock options
From March 31, 2019 to June 30, 2019 Proceeds from exercise of stock options
From December 31, 2018 to March 31, 2019 Stock purchase under ESPP Proceeds from 'at-the-market' offering, net of $34 offering expenses Proceeds from direct offering, net of $1,571 in common stock warrants, $78 offering expenses
from December 31,2017 to December 31,2018 Proceeds from "At-the-market" offering, net Proceeds from exercise of stock options Stock issuance due to warrant exercise, cashless Stock purchase under ESPP Retirement of common stock in exchange for common stock warrant
from December 31, 2017 to September 30, 2018 Stock purchase under ESPP Proceeds from 'At-the-market' offering, net Stock issuance due to warrant exercise, cashless Proceeds from exercise stock options Retirement of common stock in exchange for common stock warrant
from December 31, 2017 to June 30, 2018 Stock purchase under ESPP Stock issuance due to warrant exercise, cashless Proceeds from exercise stock options Retirement of common stock in exchange for common stock warrant
from December 31, 2017 to March 31, 2018 Stock purchase under ESPP Stock issuance due to warrant exercise, cashless
from December 31, 2016 to December 31, 2017 Proceeds from follow on offering, net of offering cost of $3,665 Proceeds from exercise of stock options Vesting of restricted stock Proceeds from "At-the-market" offering, net Proceeds from direct stock placement, net
from December 31, 2016 to September 30, 2017 Proceeds from follow on offering, net of offering cost of $3,665 Proceeds from exercise of stock options Vesting of restricted stock Proceeds from “At-the-market” offering, net
from December 31, 2016 to June 30, 2017 Proceeds from follow-on offering, net of offering costs of $3,665 Proceeds from exercise stock options Vesting of restricted stock
from December 31, 2015 to December 31, 2016 Coversion of preferred stock into common stock Proceeds from initial public offering, net of offering costs of $7,186 Exercise of stock options Vesting of restricted stock
from December 31, 2015 to September 30, 2016 Conversion of preferred stock into common stock Proceeds from IPO, net of offering costs of $7,186 Exercise of stock options Vesting of restricted stock
from December 31, 2015 to June 30, 2016 Proceeds from IPO, net of offering costs of $7,186 Conversion of preferred stock into common stock Vesting of restricted stock On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
from December 31, 2015 to March 31, 2016 Proceeds from IPO, net of offering costs of $7,186 Conversion of preferred stock into common stock Vesting of restricted stock On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
The number of shares of our common stock outstanding immediately following this offering set forth above is based on 12,972,675 shares of our common stock outstanding as of December 31, 2015 (including 14,684 shares of unvested restricted stock subject to repurchase by us), which gives effect to the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 12,872,551 shares of our common stock upon completion of this offering. On February 24, 2016, the Company effected a 1-for-1.25 reverse stock split of the Company’s outstanding common stock and convertible preferred stock.
From December 31, 2014 to December 31, 2015 Issuance of Series B-1 convertible preferred stock in January 2015 in conjunction with KHK Agreement Issuance of Series C-1 convertible preferred stock in June 2015, net of issuance costs of $0.2 million Conversion of 2014 Notes into Series C-1 Issuance of Series C-1 convertible preferred stock in August 2015, net of issuance costs of $0.2 million Exercise of stock options Vesting of restricted stock The accompanying consolidated financial statements give effect to a 1-for-1.25 reverse stock split of the common stock and convertible preferred stock of Syndax Pharmaceuticals, Inc. and subsidiaries (the “Company”), which will take place prior to the effective date of the registration statement.
from December 31, 2014 to September 30, 2015 Issuance of Series B-1 convertible preferred stock in January 2015 in conjunction with KHK Agreement Issuance of Series C-1 convertible preferred stock in June 2015, net of issuance costs of $0.2 million Conversion of 2014 Notes into Series C-1 Issuance of Series C-1 convertible preferred stock in August 2015, net of issuance costs of $0.2 million Exercise of common stock options Vesting of restricted stock
On June 3, 2014, the Company effected a 1-for-12.3 reverse stock split of the Company’s common stock and convertible preferred stock. All share and per share data shown in the accompanying interim financial statements and related notes have been retroactively revised to reflect the reverse stock split.
from December 31,2012 to December 31,2013 Conversion of Series A convertible preferred stock into Series A-1 convertible preferred stock and cancellation of warrants pursuant to the recapitalization Conversion of convertible notes and accrued interest into Series B-1 convertible preferred stock and cancellation of warrants and forced conversion into Series B convertible preferred stock pursuant to the recapitalization Issuance of Series B-1 convertible preferred stock: In March 2013, net of offering costs of $626 and tranche obligation of $206 In April 2013 In July 2013, net of tranche obligation of $754 and beneficial conversion feature of $452 In August 2013, net of offering costs of $365 and tranche obligation of $1,964 and beneficial conversion feature of $842 In November 2013, including $7,008 de-recognition of remaining tranche obligation Forced conversion of Series A-1 convertible preferred into Series A convertible preferred stock Issuance of common stock as consideration for license fees